PTC Therapeutics Inc., a South Plainfield-based a biotechnology company focused on gene therapies for rare genetic disorders of the central nervous system, announced Monday it has promoted Emily Hill to chief financial officer.
Hill joined PTC in November 2013 and most recently served as senior vice president and head of investor relations.
“It is my pleasure to announce Emily’s promotion to CFO,” PTC CEO Stuart W. Peltz said. “Emily has a deep knowledge of our industry and has strong relationships and understanding of the investor community. Emily has a great track record of leadership at PTC and will be part of the executive team to deliver value to patients and shareholders as we continue to realize our vision of bringing more treatments to patients living with rare disorders.”
Prior to PTC, Hill was the director of investor relations at Warner Chilcott. Additionally, she was senior manager of investor relations at Genzyme Corp. Before that, she was a biotech equity research associate at Summer Street Partners.
